Editas Medicine Announces Upcoming Investor Events
30 Agosto 2023 - 10:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced that management will participate
in the following upcoming investor conferences:
- 2023 Wells Fargo Healthcare ConferenceFormat:
Fireside ChatDate: Thursday, September 7Time: 3:00 p.m.
ETLocation: Boston, MA
- Morgan Stanley 21st Annual Global Healthcare
ConferenceFormat: Fireside ChatDate: Monday, September
11Time: 10:00 a.m. ETLocation: New York, NY
- Cantor Global Healthcare Conference
2023Format: Fireside ChatDate: Tuesday, September
26Time: 1:35 p.m. ETLocation: New York, NY
To access the live webcasts of Editas Medicine’s
presentations, please visit the “Investors” section of the
Company’s website at www.editasmedicine.com. An archived
replay will be available for approximately 30 days following each
event.
About Editas
MedicineAs a clinical-stage genome editing company, Editas
Medicine is focused on translating the power and potential of the
CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust
pipeline of treatments for people living with serious diseases
around the world. Editas Medicine aims to discover, develop,
manufacture, and commercialize transformative, durable, precision
genomic medicines for a broad class of diseases. Editas Medicine is
the exclusive licensee of Broad Institute’s Cas12a patent estate
and Broad Institute and Harvard University’s Cas9 patent estates
for human medicines. For the latest information and scientific
presentations, please visit www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024